HU208955B - Process for producing serotonine 5ht la agonists and pharmaceutical compositions containing them as active substance - Google Patents

Process for producing serotonine 5ht la agonists and pharmaceutical compositions containing them as active substance Download PDF

Info

Publication number
HU208955B
HU208955B HU912810A HU281091A HU208955B HU 208955 B HU208955 B HU 208955B HU 912810 A HU912810 A HU 912810A HU 281091 A HU281091 A HU 281091A HU 208955 B HU208955 B HU 208955B
Authority
HU
Hungary
Prior art keywords
formula
compound
priority
preparation
august
Prior art date
Application number
HU912810A
Other languages
English (en)
Hungarian (hu)
Other versions
HUT59092A (en
Inventor
Ian Alexander Mcdonald
Ronald Charles Bernotas
Mark William Dudley
Jeffrey Scott Sprouse
Original Assignee
Merrell Dow Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merrell Dow Pharma filed Critical Merrell Dow Pharma
Publication of HUT59092A publication Critical patent/HUT59092A/hu
Publication of HU208955B publication Critical patent/HU208955B/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/20—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring with substituents attached to the hetero ring

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
HU912810A 1990-08-29 1991-08-28 Process for producing serotonine 5ht la agonists and pharmaceutical compositions containing them as active substance HU208955B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US57471090A 1990-08-29 1990-08-29
US07/735,700 US5189179A (en) 1990-08-29 1991-07-30 Serotonin 5ht1a agonists

Publications (2)

Publication Number Publication Date
HUT59092A HUT59092A (en) 1992-04-28
HU208955B true HU208955B (en) 1994-02-28

Family

ID=27076473

Family Applications (1)

Application Number Title Priority Date Filing Date
HU912810A HU208955B (en) 1990-08-29 1991-08-28 Process for producing serotonine 5ht la agonists and pharmaceutical compositions containing them as active substance

Country Status (21)

Country Link
US (3) US5189179A (cg-RX-API-DMAC7.html)
EP (1) EP0478954B1 (cg-RX-API-DMAC7.html)
JP (1) JPH04270264A (cg-RX-API-DMAC7.html)
KR (1) KR920004345A (cg-RX-API-DMAC7.html)
CN (1) CN1030766C (cg-RX-API-DMAC7.html)
AT (1) ATE197040T1 (cg-RX-API-DMAC7.html)
AU (1) AU641535B2 (cg-RX-API-DMAC7.html)
CA (1) CA2049803A1 (cg-RX-API-DMAC7.html)
DE (1) DE69132450T2 (cg-RX-API-DMAC7.html)
DK (1) DK0478954T3 (cg-RX-API-DMAC7.html)
ES (1) ES2153346T3 (cg-RX-API-DMAC7.html)
FI (1) FI914065L (cg-RX-API-DMAC7.html)
GR (1) GR3035062T3 (cg-RX-API-DMAC7.html)
HU (1) HU208955B (cg-RX-API-DMAC7.html)
IE (1) IE913036A1 (cg-RX-API-DMAC7.html)
IL (1) IL99306A (cg-RX-API-DMAC7.html)
NO (1) NO175430C (cg-RX-API-DMAC7.html)
NZ (1) NZ239521A (cg-RX-API-DMAC7.html)
PH (1) PH30242A (cg-RX-API-DMAC7.html)
PT (1) PT98800B (cg-RX-API-DMAC7.html)
TW (1) TW200457B (cg-RX-API-DMAC7.html)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5189179A (en) * 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
US5892112A (en) * 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
USRE38506E1 (en) 1991-10-04 2004-04-20 Sloan-Kettering Institute For Cancer Research Potent inducers of terminal differentiation and methods of use thereof
US6406859B1 (en) 1992-01-08 2002-06-18 Synaptic Pharmaceutical Corporation DNA encoding a 5-HT 1F receptor and uses thereof
GB9211277D0 (en) 1992-05-28 1992-07-15 Glaxo Group Inc Pharmaceutical compositions
GB9304632D0 (en) * 1993-03-06 1993-04-21 Wyeth John & Brother Ltd Amide derivatives
FR2707294B1 (fr) * 1993-07-06 1995-09-29 Pf Medicament Nouveaux dérivés de la 3,5-dioxo-(2H,4H)-1,2,4-triazine, leur préparation et leur application en thérapeutique humaine.
US5478572A (en) * 1994-09-06 1995-12-26 Bristol-Myers Squibb Co. Gepirone dosage form
ATE302182T1 (de) * 1996-03-29 2005-09-15 Pfizer Benkyl(idene)-lactam-derivate, deren herstellung und verwendung als selektive (ant)agonisten von 5-ht1a- und/oder 5-ht1d rezeptoren
US6586458B1 (en) 1996-08-16 2003-07-01 Pozen Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US5872145A (en) * 1996-08-16 1999-02-16 Pozen, Inc. Formulation of 5-HT agonist and NSAID for treatment of migraine
US8022095B2 (en) * 1996-08-16 2011-09-20 Pozen, Inc. Methods of treating headaches using 5-HT agonists in combination with long-acting NSAIDs
US7189753B1 (en) 1997-11-06 2007-03-13 Cady Roger K Preemptive prophylaxis of migraine
AU3476599A (en) * 1998-04-08 1999-10-25 American Home Products Corporation Indol-3-yl-cyclohexyl amine derivatives for the treatment of depression (5-ht1 receptor antagonists)
AU3479299A (en) * 1998-04-08 1999-10-25 American Home Products Corporation N-aryloxyethyl-indoly-alkylamines for the treatment of depression
US6121307A (en) 1998-04-08 2000-09-19 American Home Products Corp. N-aryloxyethyl-indoly-alkylamines for the treatment of depression
CN1304403A (zh) * 1998-04-08 2001-07-18 美国家用产品公司 用于治疗抑郁症的n－芳氧基乙基－吲哚基－烷基胺(5－ht1a受体活化剂)
US6150533A (en) * 1998-04-08 2000-11-21 American Home Products Corp. N-aryloxyethyl-indoly-alkylamines for the treatment of depression
US7588029B2 (en) * 2000-03-21 2009-09-15 Fisher & Paykel Healthcare Limited Humidified gases delivery apparatus
EP1423509A2 (en) * 2001-08-30 2004-06-02 Stem Cell Therapeutics Inc. Differentiation of neural stem cells and therapeutic use thereof
ATE541921T1 (de) * 2001-09-14 2012-02-15 Stem Cell Therapeutics Inc Prolaktin-induzierte zunahme an neuronalen stammzellen und dessen therapeutische anwendung
WO2003024471A2 (en) * 2001-09-18 2003-03-27 Stem Cell Therapeutics Inc. Effect of growth hormone and igf-1 on neural stem cells and therapeutic application
AU2003250705A1 (en) * 2002-07-31 2004-02-16 Stem Cell Therapeutics Inc. Method of enhancing neural stem cell proliferation, differentiation, and survival using pituitary adenylate cyclase activating polypeptide (pacap)
MXPA05006954A (es) * 2002-12-26 2005-09-22 Pozen Inc Formas de dosificacion de capas multiples que contienen nsaids y triptanos.
US20070184109A1 (en) * 2003-06-06 2007-08-09 Floyd Alison G Compositions comprising triptans and nsaids
WO2005018541A2 (en) * 2003-07-11 2005-03-03 Pharmacia Corporation Cox-2 inhibitor and serotonin modulator for treating cns damage
US20070111932A1 (en) * 2003-07-31 2007-05-17 Stem Cell Therapeutics Inc. Method of enhancing and/or inducing neuronal migration using erythropoietin
BRPI0413679A (pt) * 2003-08-22 2006-10-24 Pharmacia Corp formulações de um inibidor seletivo da ciclooxigenase-2 e de um agente de modulação da serotonina para o tratamento da neoplasia
CN1325673C (zh) * 2003-12-30 2007-07-11 上海交通大学 利用废旧紫铜生产无氧铜的装置
US7846898B2 (en) * 2004-02-13 2010-12-07 Stem Cell Therapeutics Corp. Pheromones and the luteinizing hormone for inducing proliferation of neural stem cells and neurogenesis
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
BRPI0610864A2 (pt) 2005-05-20 2010-08-03 Janssen Pharmaceutica Nv processo para preparação de derivados de sulfamida
JP2009509943A (ja) 2005-09-27 2009-03-12 ステム セル セラピューティクス コーポレイション プロラクチンにより制御される乏突起膠細胞前駆体細胞の増殖
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
US20070191474A1 (en) * 2006-02-15 2007-08-16 Smith-Swintosky Virginia L Use of benzo-fused heterocyle sulfamide derivatives for the treatment of migraine
AU2007229301B2 (en) 2006-03-17 2013-08-01 Stem Cell Therapeutics Corp. Continuous dosing regimens for neural stem cell proliferating agents and neural stem cell differentiating agents
US8853263B2 (en) 2006-05-19 2014-10-07 Janssen Pharmaceutica Nv Co-therapy for the treatment of epilepsy and related disorders
CA2729056A1 (en) 2008-06-23 2010-01-21 Janssen Pharmaceutica Nv Crystalline form of (2s)-(-)-n-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
CN111116451A (zh) * 2020-01-16 2020-05-08 宁波大学 一种多取代色胺基苯甲酰胺类化合物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2725386A (en) * 1953-02-13 1955-11-29 Fond Emanuele Paterno 2-(1, 4-benzodioxan) methyl derivatives of amino-lower fatty acid amides and preparation thereof
FR2463765A1 (fr) * 1979-08-17 1981-02-27 Clin Midy Nouveaux derives de l'indole actifs sur le systeme cardiovasculaire
US4684739A (en) * 1980-12-15 1987-08-04 Mitsubishi Chemical Industries Limited Alkylenedioxybenzene derivatives and acid addition salts thereof
US4614807A (en) * 1984-10-04 1986-09-30 Eli Lilly And Company 6,7-dihalomelatonins
ATE65084T1 (de) * 1986-06-26 1991-07-15 Ciba Geigy Ag Hydrierte 1-benzooxacycloalkylpyridincarbons|ureverbindungen.
DE3642497A1 (de) 1986-12-12 1988-06-23 Hoechst Ag Substituierte aminopropionsaeureamide, verfahren zu ihrer herstellung, diese enthaltende mittel und ihre verwendung sowie die bei der herstellung anfallenden neuen zwischenprodukte
US4956382A (en) * 1987-02-07 1990-09-11 Pfizer Inc. Sulfonamide anti-arrhythmic agents
US5189179A (en) * 1990-08-29 1993-02-23 Merrell Dow Pharmaceuticals Inc. Serotonin 5ht1a agonists
US5120758A (en) * 1991-02-08 1992-06-09 Ciba-Geigy Corporation Certain benzodioxole, benzodioxane and benzodioxepin derivatives useful as 5-lipoxygenase inhibitors

Also Published As

Publication number Publication date
ES2153346T3 (es) 2001-03-01
NO913384L (no) 1992-03-02
KR920004345A (ko) 1992-03-27
NO175430B (no) 1994-07-04
CA2049803A1 (en) 1992-03-01
CN1030766C (zh) 1996-01-24
US5189179A (en) 1993-02-23
PT98800A (pt) 1992-08-31
IL99306A (en) 1995-03-30
IL99306A0 (en) 1992-07-15
EP0478954B1 (en) 2000-10-18
DE69132450D1 (de) 2000-11-23
AU8266491A (en) 1992-03-05
NO913384D0 (no) 1991-08-28
EP0478954A1 (en) 1992-04-08
JPH04270264A (ja) 1992-09-25
FI914065A7 (fi) 1992-03-01
DE69132450T2 (de) 2001-05-03
ATE197040T1 (de) 2000-11-15
PH30242A (en) 1997-02-05
DK0478954T3 (da) 2001-01-08
CN1059717A (zh) 1992-03-25
FI914065L (fi) 1992-03-01
IE913036A1 (en) 1992-03-11
US5559143A (en) 1996-09-24
NO175430C (no) 1994-10-12
PT98800B (pt) 1999-01-29
GR3035062T3 (en) 2001-03-30
FI914065A0 (fi) 1991-08-28
NZ239521A (en) 1993-07-27
AU641535B2 (en) 1993-09-23
US5387604A (en) 1995-02-07
HUT59092A (en) 1992-04-28
TW200457B (cg-RX-API-DMAC7.html) 1993-02-21

Similar Documents

Publication Publication Date Title
HU208955B (en) Process for producing serotonine 5ht la agonists and pharmaceutical compositions containing them as active substance
JP3168565B2 (ja) ３−アミドインドリル誘導体類
US5189054A (en) 3-amidoindolyl derivatives and pharmaceutical compositions thereof
FR2714378A1 (fr) Dérivés de l'indol-2-one substitués en 3 par un groupe azoté, leur préparation, les compositions pharmaceutiques en contenant.
BG100040A (bg) Индолови производни като 5-нт1а и/или 5-нт2 лиганди
JP2006524641A (ja) 置換されたインドリンおよびインドール誘導体
TWI249402B (en) 2,7-substituted indoles
JP4950157B2 (ja) Ｔ型カルシウムチャンネルに活性を有した新規イソインドリノン誘導体及びその製造方法
IL203956A (en) Indole-2-on-2 derivatives are positioned in position 3, their preparation and use for drug preparation
AU2009330131B2 (en) Compounds and methods for the treatment of pain and other diseases
EP0526478B1 (en) 3-indolyl thioacetate derivatives
DK2521714T3 (en) Aromatic sulfone compositions useful in the treatment of central nervous disorders
JP2669765B2 (ja) （１ｈ−インドール−１−イル）−２−（アミノ）アセトアミドおよび関連した（１ｈ−インドール−１−イル）−（アミノアルキル）アミド、中間体およびそれらの製法ならびにそれらを含有する神経保護剤
PL212987B1 (pl) Nowe pochodne indolu, kompozycja farmaceutyczna oraz zastosowanie nowych pochodnych indolu
JP4098523B2 (ja) Ｃｎｓ障害に対するカルボニルアミノ誘導体の使用
CA2266556C (en) Nmda (n-methyl-d-aspartate) antagonists
FR2593818A1 (fr) Derives d'acylaminomethyl-3 imidazo(1,2-a)pyridine, leur preparation et leur application en therapeutique
JPH068285B2 (ja) 三環式アミン、その製法及び医薬組成物
US5922752A (en) NMDA (n-methyl-d-aspartate) antagonists
WO1993013766A1 (en) Treatment of involuntary movements with 5ht1a receptor agonists
US20040082615A1 (en) 3-Imino-2-indolones for the treatement of depression and/or anxiety
JP2002504893A (ja) Ｎ−ヘテロ環グリオキサミド化合物を用いた脳卒中の治療方法
MXPA99002983A (en) Nmda (n-methyl-d-aspartate) antagonists

Legal Events

Date Code Title Description
HMM4 Cancellation of final prot. due to non-payment of fee